Status:
COMPLETED
Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Lead Sponsor:
EHL Bio Co., Ltd.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
19-70 years
Brief Summary
This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patient...
Detailed Description
Participants will be followed-up for adverse events on each visit. Visits will be on 6, 12, 18, 24, 30, 36, 48, 60months after treatment of ADSTEM Inj. Time perspective is both retrospective and pros...
Eligibility Criteria
Inclusion
- Patients who participated in Phase I clinical trials
- Patients who voluntarily agreed to participate in the study
Exclusion
- Patients who can not follow-up from the end of the phase 1 clinical trial to the end of the study
Key Trial Info
Start Date :
September 19 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 27 2022
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03252340
Start Date
September 19 2017
End Date
September 27 2022
Last Update
February 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungnam National University Hospital
Daejeon, Chungcheongnam-do, South Korea